论文部分内容阅读
目的:探讨大黄素干预对于肝硬化门脉高压大鼠肠屏障表达HSP70的差异。方法:SD雄性大鼠30只,随机均分为正常对照(A)组、肝硬化模型(B)组、大黄素干预(C)组,500m L/L CCl4(3m L/100g)皮下注射8周复制肝硬化大鼠模型,C组在制作模型第15天起同时每日大黄素(5mg/m L,5m L/kg)灌胃,1次/d,A组大鼠给予0.9%氯化钠溶液(3m L/100g)皮下注射,A、B组每日给予相当体积的0.9%氯化钠溶液灌胃,8周后处死大鼠,测定门脉压力,取末端回肠组织观察组织病理学改变、血清生化指标测定,肝脏、肠道HSP70的表达。结果:B组小肠黏膜损伤镜下观察重于A组,而C组小肠黏膜损伤较B组减轻;与A组比较,B组门脉压力显著升高(P<0.05),大鼠明显处于高循环状态,B组血清生化指标(ALT、AST、ALB、TB、ALP)水平显著升高(P<0.05);与B组比较,C组门脉压力明显降低(P<0.05),C组生化指标明显降低(P<0.05);肝脏、肠道HSP70的表达B组明显低于A组,而C组较B组明显增高(P<0.05)。结论:应用大黄素干预门脉高压大鼠后,大鼠的门脉压力有明显的下降,大黄素组大鼠肝功能明显好转,肝脏表达HSP70上调,光镜下小肠黏膜损伤减轻,肠道表达HSP70水平均明显上调,大黄素对于肝硬化门脉高压大鼠通过上调HSP70表达保护其屏障功能。
Objective: To investigate the difference of emodin intervention on HSP70 expression in gut barrier of cirrhotic rats with portal hypertension. Methods: Thirty SD male rats were randomly divided into normal control group (A), cirrhosis model group (B), emodin intervention group (C) and 500m L / L CCl4 (3m L / 100g) The rat model of liver cirrhosis was duplicated. In group C, daily emodin (5mg / m L, 5m L / kg) Sodium chloride solution (3m L / 100g) was injected subcutaneously. Groups A and B were orally administered with 0.9% sodium chloride solution daily for 8 weeks. The portal vein pressure was measured and the terminal ileum tissue was observed for histopathology Changes, serum biochemical markers, liver, intestinal HSP70 expression. Results: The damage of intestinal mucosa in group B was more severe than that in group A, but the damage in group C was less than that in group B. Compared with group A, the portal pressure of group B was significantly increased (P <0.05) and significantly higher in group B The levels of serum biochemical markers (ALT, AST, ALB, TB, ALP) in group B were significantly higher than those in group B (P <0.05). Compared with group B, portal pressure in group C was significantly lower (P <0.05) (P <0.05). The expression of HSP70 in liver and intestine in group B was significantly lower than that in group A, but was significantly higher in group C than that in group B (P <0.05). CONCLUSION: Emodin can significantly decrease the portal pressure of rats with portal hypertension, improve the liver function of rats in emodin group, up-regulate the expression of HSP70 in liver, alleviate the damage of intestinal mucosa under light microscope, HSP70 levels were significantly increased, emodin in cirrhotic rats with portal hypertension by upregulating the expression of HSP70 to protect its barrier function.